Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets

By P. Vihinen, V. Kähäri. International Journal of Cancer, 2002

674 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Extracellular matrix structure. (2016, background): “To start, metalloproteases produced by several cell types such as fibroblasts, epithelial, endothelial inflammatory and cancer cells are responsible for the catabolism of almost all ECM molecules [286], as well as non-ECM cell regulators [287, 288].”
Urothelial tumorigenesis: a tale of divergent pathways (2005, background): “The matrix metalloproteinases (MMPs) are proteolytic enzymes that can degrade the extracellular matrix and basement membranes, and have crucial roles in tumour invasio”
Studies on anticancer activities of antimicrobial peptides. (2008, background): “One strategy is based on the use of matrix metalloproteinase-2, which is over expressed by human cancer cells and tumorassociated endothelium [144], to selectively cleave a melittin– avidin conjugate, thereby restoring the lytic function of melittin at the site of matrix metalloprotease-2 expression”